Sample Preparation System facilitates molecular testing.
Press Release Summary:
Based on Biomek® automation and diagnostic primary tube handling technologies, Vidiera(TM) NsP Nucleic Sample Preparation platform provides nucleic acid isolation, quantification, normalization, and reaction set-up for downstream assay analysis. Suited for molecular diagnostic applications in virology and pathology, Vidiera NsP enables hospital and reference labs to centralize pre-analytical functions in one room and streamline process.
Original Press Release:
Beckman Coulter Ships New Nucleic Acid Sample Preparation Platform for Molecular Diagnostic Labs
FULLERTON, Calif., Oct. 4 / -- Beckman Coulter, Inc. (NYSE:BEC) has begun shipping its new Vidiera(TM) NsP Nucleic Sample Preparation platform, a versatile new solution for nucleic acid isolation, quantification, normalization and reaction set-up for downstream assay analysis. Vidiera NsP is based on Beckman Coulter's proven Biomek(R) automation and diagnostic primary tube handling technologies and is specifically designed to meet the growing need for molecular testing in hospital and reference laboratories.
Vidiera NsP is ideal for molecular diagnostic applications in virology and pathology and can be integrated with Beckman Coulter's recently announced Vidiera NsD Nucleic Sample Detection System. Capable of setting-up reactions for most major downstream analytical instruments that molecular diagnostic laboratories have today, Vidiera NsP can enable labs to centralize pre-analytical functions in one room and streamline the process.
"Our new Vidiera products bring together our expertise in clinical diagnostics and research laboratory automation to benefit the growing field of molecular testing," explained Bruce Wallace, vice president, nucleic acid testing business for Beckman Coulter. "This product line is a clear example of our biomedical testing continuum strategy and demonstrates the advantage our broad range of expertise gives us in bringing new solutions to the diagnostics marketplace."
Vidiera NsP is currently only available in the United States and will be marketed to high-complexity diagnostic labs.
Beckman Coulter, Inc. is a leading manufacturer of biomedical testing instrument systems, tests and supplies that simplify and automate laboratory processes. Spanning the biomedical testing continuum -- from pioneering medical research and clinical trials to laboratory diagnostics and point-of-care testing -- Beckman Coulter's 200,000 installed systems provide essential biomedical information to enhance health care around the world. The company, based in Fullerton, Calif., reported 2004 annual sales of $2.4 billion with 64 percent of this amount generated by recurring revenue from supplies, test kits and services. For more information, visit www.beckmancoulter.com.
